Tier 1 — highest

The effect of quercetin supplementation on clinical outcomes in COVID-19 patients: A systematic review and meta-analysis

Somayeh Ziaei, Malek Alimohammadi-Kamalabadi, Motahareh Hasani, Mahsa Malekahmadi, Emma Persad, Javad Heshmati
Food science & nutrition 2023 11(12):7504-7514

Bibliography

PubMed
PMID 38107099
PubMed Central
PMC10724618
DOI
10.1002/fsn3.3715
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors have no competing interests to declare.

Study snapshot

DesignSystematic review and meta-analysis of randomized COVID-19 trials
ModelHuman evidence synthesis
Sample5 studies; 544 patients
InterventionQuercetin-containing regimens
DurationSearches through August 25, 2023
EndpointsInflammatory measures; Events and survival

What the study showed, in plain terms

Published in 2023, this source examined immunity and respiratory health. Its evidence base was 5 studies; 544 patients. It evaluated Quercetin-containing regimens across Searches through August 25, 2023.

Pooled admission and mortality estimates favored supplementation; several inflammatory markers did not improve.

Mortality estimates were based on few events with wide intervals and differed from another review. Small trials and potentially overlapping reports prevent a firm treatment claim.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pooled admission and mortality estimates favored supplementation; several inflammatory markers did not improve.
  • The recorded outcome domains were Inflammatory measures; Events and survival.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Mortality estimates were based on few events with wide intervals and differed from another review. Small trials and potentially overlapping reports prevent a firm treatment claim.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis
Huzaifa Ahmad Cheema et al. · Reviews in medical virology · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology